Skip to main content
Equibles
CRSP logo

CRSP · CRISPR Therapeutics AG · Metrics

Track CRSP — free

Use CRSP with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$54.78 -1.01 (-1.81%) At close · Sep 8
Russell 2000 member Rebalance outlook locked
Market Cap
$5.39B
Shares
96.69M

CRSP metrics

67 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$54.78
Market cap
$5.39B

Price action

20 metrics
Price change (1W)
-3.3%
Price change (30D)
+4.3%
Price change (3M)
+7.6%
Price change (6M)
-1.3%
Price change (YTD)
+6.4%
Price change (1Y)
+5.8%
Trailing year
Price change (5Y)
-54.3%
52-week high
$76.78
52-week low
$44.34
Change from 52-week high
-27.3%
Change from 52-week low
+25.8%
Annualized volatility
60.0%
Annualized volatility (3M)
54.2%
Beta
1.8
RSI (14D)
50.7
Price vs SMA 50
+3.8%
Price vs SMA 200
+4.8%
Avg volume (3M)
1.59M
Relative volume
0.6
Average dollar volume
$85.42M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
96.69M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
270.0×
reciprocal yield 0.4%
EV / EBITDA
—
EV / EBIT
—
P / sales
402.8×
reciprocal yield 0.2%
P / book
3.1
reciprocal yield 32.4%
FCF yield
-6.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-8.4%

Historical valuation

8 metrics
P / E historical average (3Y)
39.5×
reciprocal yield 2.5%
P / E historical average (5Y)
39.5×
reciprocal yield 2.5%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-3,990.0%
Trailing 12 months
Net margin
-3,368.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$534.34M
Net income (TTM)
−$451.14M
Trailing 12 months
Diluted EPS (TTM)
$-4.71
FCF margin
-2,772.7%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-5.26

Growth

11 metrics
Revenue growth YoY
+1,041.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$13.39M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+10.8%
Year over year · more shares
Revenue CAGR (3Y)
+43.1%
Revenue CAGR (5Y)
+37.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-25.8%
Return on assets
-17.0%
Debt / equity
0.3
Current ratio
17.8
EBITDA (TTM)
−$515.65M
Free cash flow (TTM)
−$371.32M
Quick ratio
17.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.78B
Latest balance sheet
Cash & equivalents
$291.34M
Total assets
$2.65B
Total debt
$586.20M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$369.58M
Capital expenditures (TTM)
$1.74M
R&D (TTM)
$278.15M
SG&A (TTM)
—
Stock compensation (TTM)
$68.32M
R&D / revenue
2,077.0%
Stock compensation / revenue
510.2%

Ownership (13F)

3 metrics
13F filers
527
13F filer change QoQ
+26
Institutional ownership
81.5%

Short interest

3 metrics
Short interest
19.4%
Latest settlement · 15.6 days to cover
Days to cover
15.6d
Short-squeeze score
71 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1674416 CUSIP H17182108 13F (30d) 277 filings 275 filers Visit website Investor relations